CSIMarket
 


Atyr Pharma Inc  (LIFE)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

LIFE's Revenue Growth by Quarter and Year

Atyr Pharma Inc's Revenue results by quarter and year




LIFE Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December 2.05 0.14 - -
III Quarter September 0.15 0.18 - -
II Quarter June 0.19 0.09 - -
I Quarter March 8.07 - - -
FY   10.46 0.41 - -



LIFE Revenue forth quarter 2020 Y/Y Growth Comment
Atyr Pharma Inc achieved in the forth quarter, above Company average Revenue surge of 1366.43% year on year, to $ 2.05 millions.

Looking into forth quarter results within Biotechnology & Drugs industry 21 other companies have achieved higher Revenue growth. While Atyr Pharma Inc' s Revenue doubling of 1366.43% ranks overall at the positon no. 247 in the forth quarter.




LIFE Revenue ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December 1366.43 % - - -
III Quarter September -16.67 % - - -
II Quarter June 111.11 % - - -
I Quarter March - - - -
FY   2451.95 % - - -

Financial Statements
Atyr Pharma Inc's forth quarter 2020 Revenue $ 2.05 millions LIFE's Income Statement
Atyr Pharma Inc's forth quarter 2019 Revenue $ 0.14 millions Quarterly LIFE's Income Statement
New: More LIFE's historic Revenue Growth >>


LIFE Revenue (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December 1268.67 % -22.22 % - -
III Quarter September -21.05 % 100 % - -
II Quarter June -97.65 % - - -
I Quarter March 5664.29 % - - -
FY (Year on Year)   2451.95 % - - -




Revenue forth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #22
Healthcare Sector #68
Overall #247

Revenue Y/Y Growth Statistics
High Average Low
22.34 % 2.92 % -0.93 %
(Dec 31 2020)   (Dec. 31, 2008)
Revenue forth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #22
Healthcare Sector #68
Overall #247
Revenue Y/Y Growth Statistics
High Average Low
22.34 % 2.92 % -0.93 %
(Dec 31 2020)   (Dec. 31, 2008)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Atyr Pharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
5500.69 % 166.54 % -97.66 %
(Mar 31 2020)  


LIFE's IV. Quarter Q/Q Revenue Comment
Atyr Pharma Inc achieved in the IV. Quarter 2020 above company average sequential Revenue doubling of 1268.67%, to $ 2.05 millions, from $0.15 millions in the third quarter.
LIFE is impressively improving, not only recording higher then average increase, but also increasing rate, Thomas  Williams, market veteran said.

Within Biotechnology & Drugs industry only one company achieved higher sequential Revenue growth. While Atyr Pharma Inc's Revenue growth quarter on quarter, overall rank is 17.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #7
Overall #17
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #7
Overall #17
Revenue Q/Q Growth Statistics
High Average Low
5500.69 % 166.54 % -97.66 %
(Mar 31 2020)  


LIFE's IV. Quarter Q/Q Revenue Comment
Atyr Pharma Inc achieved in the IV. Quarter 2020 above company average sequential Revenue doubling of 1268.67%, to $ 2.05 millions, from $0.15 millions in the third quarter.
LIFE is undergoing a remarkable growth, with claiming higher then average increase, and additionally accelerating rate, Thomas  Williams, market veteran said.

Within Biotechnology & Drugs industry only one company achieved higher sequential Revenue growth. While Atyr Pharma Inc's Revenue growth quarter on quarter, overall rank is 17.


Atyr Pharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
Cumulative Revenue 12 Months Ending $ 10.46 $ 8.55 $ 8.58 $ 8.49 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 22.34 % -0.42 % 1.12 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 247 # 2108 # 896 # 0 # 0




Cumulative Revenue growth Comment
Atyr Pharma Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 1366.43% year on year, to $ 10 millions if the fiscal year would have ended in Dec 31 2020.
Atyr Pharma Inc's trailing twelve months Revenue growth was higher than company's average 10.77% and higher than % growth in Sep 30 2020. And, Atyr Pharma Inc realized the fastest Revenue growth, in Biotechnology & Drugs industry.
But sequential increase was slower at 22.34 % from $8.55 millions achieved in twelve months ending a quarter Sep 30 2020.
Still this was confirmation of positive momentum, while the typical sequential advancement stands at 2.92%.
The progress was even higher from the previous reporting period showed at 22.34 % jump from $8.55 millions in twelve months ending a quarter before.

Atyr Pharma Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
22.34 %
2.92 %
-0.93 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
44.25 %
10.77 %
-0.57 %
(Dec. 31, 2009)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 68
S&P 500 # 247
Cumulative Revenue growth Comment
Atyr Pharma Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 1366.43% year on year, to $ 10 millions if the fiscal year would have ended in Dec 31 2020.
Atyr Pharma Inc's trailing twelve months Revenue growth was higher than company's average 10.77% and higher than % growth in Sep 30 2020. And, Atyr Pharma Inc realized the fastest Revenue growth, in Biotechnology & Drugs industry.
But sequential rise was beneth at 22.34 % from $8.55 millions achieved in the period from Sep 30 2020 to Dec 31 2019.
Still it was evidence of positive momentum, while the typical Q/Q TTM growth lays at 2.92%.
The progress was even more impressive sequentially clinched at 22.34 % jump from $8.55 millions in twelve months ending a quarter before.

Atyr Pharma Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
22.34 %
2.92 %
-0.93 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
44.25 %
10.77 %
-0.57 %
(Dec. 31, 2009)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 68
S&P 500 # 247




Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LIFE's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for LIFE's Competitors
Revenue Growth for Atyr Pharma Inc's Suppliers
Revenue Growth for LIFE's Customers

You may also want to know
LIFE's Annual Growth Rates LIFE's Profitability Ratios LIFE's Asset Turnover Ratio LIFE's Dividend Growth
LIFE's Roe LIFE's Valuation Ratios LIFE's Financial Strength Ratios LIFE's Dividend Payout Ratio
LIFE's Roa LIFE's Inventory Turnover Ratio LIFE's Growth Rates LIFE's Dividend Comparisons



Companies with similar Revenue doubling for the quarter ending Dec 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2020
Anaptysbio inc1,900.00%$ 1,900.000 millions
Global Blood Therapeutics Inc 1,858.97%$ 1,858.966 millions
Atyr Pharma Inc1,325.69%$ 1,325.694 millions
Xencor Inc1,090.39%$ 1,090.387 millions
General Cannabis Corp1,069.07%$ 1,069.066 millions
Intelgenx Technologies Corp 1,061.76%$ 1,061.765 millions
Skinvisible Inc 1,043.95%$ 1,043.951 millions
Redhawk Holdings Corp 1,038.89%$ 1,038.887 millions
Syros Pharmaceuticals inc 1,021.65%$ 1,021.654 millions
Biocept Inc937.78%$ 937.775 millions
Redhill Biopharma Ltd 923.03%$ 923.033 millions
Esperion Therapeutics Inc 881.47%$ 881.466 millions
Mei Pharma Inc 809.42%$ 809.425 millions
Xenetic Biosciences Inc 786.75%$ 786.746 millions
Siga Technologies Inc784.83%$ 784.835 millions
Navidea Biopharmaceuticals Inc 780.84%$ 780.844 millions
Zymeworks Inc 735.38%$ 735.376 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MVIS's Profile

Stock Price

MVIS's Financials

Business Description

Fundamentals

Charts & Quotes

MVIS's News

Suppliers

MVIS's Competitors

Customers & Markets

Economic Indicators

MVIS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071